LETTER
Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease
1 Department of Biomedical Sciences, University of Trieste, and Department of Reproductive and Developmental Sciences and IRCCS, Istituto per I’Infanzia Burlo Garofolo, Clinica Pediatrica, Trieste, Italy
2 Department of Reproductive and Developmental Sciences and IRCCS, Istituto per I’Infanzia Burlo Garofolo, Clinica Pediatrica, Trieste, Italy
3 Department of Biomedical Sciences, University of Trieste, and Department of Reproductive and Developmental Sciences and IRCCS, Istituto per L’Infanzia Burlo Garofolo, Clinica Pediatrica, Trieste, Italy
4 Department of Reproductive and Developmental Sciences and IRCCS, Istituto per I’Infanzia Burlo Garofolo, Clinica Pediatrica, Trieste, Italy
5 Research Children’s Hospital ‘Meyer’, Florence, Italy
6 Research Children’s Hospital ‘Gaslini’, Genoa, Italy
7 Department of Biomedical Sciences, University of Trieste, Italy
8 Department of Reproductive and Developmental Sciences and IRCCS, Istituto per I’Infanzia Burlo Garofolo, Clinica Pediatrica, Trieste, Italy
Correspondence to:
Correspondence to:
Dr Giuliana Decorti
Department of Biomedical Sciences, University of Trieste, Via L Giorgieri 7, 9, 34127 Trieste, Italy; decorti@units.it
| The first 150 words of the full text of this article appear below. |
Glucocorticoids (GCs) are immunosuppressive drugs used for the acute treatment of patients with moderate to severe inflammatory bowel disease (IBD),1 but interindividual variability in the response to these agents is frequently observed.2 GCs diffuse freely into cells and bind to an intracellular receptor (hGR/NR3C1), so the sensitivity to these drugs may depend on the receptor number and affinity or on their availability to the receptors, and transport proteins (including P-glycoprotein (Pgp) encoded by the MDR1/ABCB1 gene) can modify their intracellular concentration.3,4 Polymorphisms in the hGR and MDR1 genes have been described in different populations and may contribute to the variability in sensitivity to GCs observed in the clinical setting.3,4
A study was conducted to estimate the impact of genetic variations in hGR and MDR1 genes on the efficacy and individual response to GCs in young patients with IBD. Polymorphisms of the hGR gene (BclI and N363S which are
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Alert me when this article is cited
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
